marketcaparena
Search

    REGN

    REGENERON PHARMACEUTICALS, INC.

    Company overview

    Market capitalization
    —
    Employees
    15,343
    Latest publication
    2026-09-29
    About REGENERON PHARMACEUTICALS, INC.

    Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue4,290,700,000USD3,605,400,000USD3,884,300,000USD3,754,300,000USD3,675,600,000USD3,028,700,000USD3,789,200,000USD3,720,700,000USD
    Cost Of Revenue576,500,000USD669,400,000USD584,600,000USD521,600,000USD530,200,000USD464,300,000USD565,400,000USD491,100,000USD
    Gross Profit3,714,200,000USD2,936,000,000USD3,299,700,000USD3,232,700,000USD3,145,400,000USD2,564,400,000USD3,223,800,000USD3,229,600,000USD
    Research Development1,631,600,000USD1,645,400,000USD1,626,100,000USD1,558,100,000USD1,431,700,000USD1,339,700,000USD1,425,900,000USD1,327,700,000USD
    Selling General Administrative662,100,000USD647,700,000USD775,000,000USD657,800,000USD634,200,000USD633,000,000USD792,200,000USD714,400,000USD
    Other Operating Expenses703,500,000USD———————
    Total Operating Expenses2,997,200,000USD2,293,100,000USD2,419,800,000USD2,205,900,000USD2,065,900,000USD1,972,700,000USD2,233,600,000USD2,050,100,000USD
    Operating Income1,293,500,000USD642,900,000USD879,900,000USD1,026,800,000USD1,079,500,000USD591,700,000USD990,200,000USD1,179,500,000USD
    Total Other Income Expense Net234,300,000USD188,300,000USD163,800,000USD736,500,000USD439,200,000USD313,300,000USD-32,100,000USD313,500,000USD
    Interest Income183,300,000USD183,500,000USD193,300,000USD175,100,000USD174,800,000USD173,500,000USD183,100,000USD187,400,000USD
    Interest Expense11,000,000USD12,900,000USD12,200,000USD19,300,000USD3,600,000USD8,700,000USD10,500,000USD13,800,000USD
    Income Before Tax1,527,800,000USD831,200,000USD1,043,700,000USD1,763,300,000USD1,518,700,000USD905,000,000USD958,100,000USD1,493,000,000USD
    Income Tax Expense230,900,000USD104,000,000USD199,100,000USD303,300,000USD127,100,000USD96,300,000USD40,400,000USD152,400,000USD
    Net Income1,296,900,000USD727,200,000USD844,600,000USD1,460,000,000USD1,391,600,000USD808,700,000USD917,700,000USD1,340,600,000USD
    Net Interest Income—170,600,000USD181,100,000USD155,800,000USD171,200,000USD164,800,000USD172,600,000USD173,600,000USD
    Tax Provision—104,000,000USD199,100,000USD303,300,000USD127,100,000USD96,300,000USD40,400,000USD152,400,000USD
    Net Income From Continuing Ops—727,200,000USD844,600,000USD1,460,000,000USD1,391,600,000USD808,700,000USD917,700,000USD1,340,600,000USD
    Ebit—844,100,000USD1,055,900,000USD1,782,600,000USD1,522,300,000USD913,700,000USD968,600,000USD1,506,800,000USD
    Ebitda—967,300,000USD1,200,900,000USD1,919,300,000USD1,657,400,000USD1,040,600,000USD1,095,000,000USD1,628,500,000USD
    Depreciation And Amortization—123,200,000USD145,000,000USD136,700,000USD135,100,000USD126,900,000USD126,400,000USD121,700,000USD
    Reconciled Depreciation—123,200,000USD145,000,000USD136,700,000USD135,100,000USD126,900,000USD126,400,000USD121,700,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue14,342,900,000USD14,202,000,000USD13,117,200,000USD12,172,900,000USD16,071,700,000USD8,497,100,000USD7,863,400,000USD6,710,800,000USD
    Cost Of Revenue2,100,700,000USD1,970,500,000USD883,700,000USD1,705,200,000USD2,723,700,000USD1,355,800,000USD782,200,000USD434,100,000USD
    Gross Profit12,242,200,000USD12,231,500,000USD12,233,500,000USD10,467,700,000USD13,348,000,000USD7,141,300,000USD7,081,200,000USD6,276,700,000USD
    Research Development5,850,200,000USD5,233,000,000USD4,439,000,000USD3,056,100,000USD2,621,900,000USD2,499,100,000USD3,036,600,000USD2,186,100,000USD
    Selling General Administrative2,700,000,000USD2,954,400,000USD2,554,100,000USD2,115,900,000USD1,824,900,000USD1,346,000,000USD1,834,800,000USD1,556,200,000USD
    Unclassified Operating Expenses114,100,000USD—77,200,000USD-89,900,000USD-45,600,000USD-280,400,000USD——
    Total Operating Expenses8,664,300,000USD8,240,800,000USD7,070,300,000USD5,082,100,000USD4,401,200,000USD3,564,700,000USD4,871,400,000USD3,742,300,000USD
    Operating Income3,577,900,000USD3,990,700,000USD4,047,100,000USD5,385,600,000USD8,946,800,000USD3,576,600,000USD2,209,800,000USD2,534,400,000USD
    Interest Income716,800,000USD711,400,000USD417,700,000USD160,100,000USD45,800,000USD—88,100,000USD13,700,000USD
    Interest Expense43,800,000USD55,200,000USD73,000,000USD59,400,000USD57,300,000USD56,900,000USD30,200,000USD28,200,000USD
    Net Interest Income673,000,000USD656,200,000USD345,600,000USD100,700,000USD-57,300,000USD-56,900,000USD-30,200,000USD-28,200,000USD
    Income Before Tax5,230,700,000USD4,779,900,000USD4,199,300,000USD4,858,800,000USD9,325,800,000USD3,810,400,000USD2,429,100,000USD2,553,500,000USD
    Income Tax Expense725,800,000USD367,300,000USD245,700,000USD520,400,000USD1,250,500,000USD297,200,000USD313,300,000USD109,100,000USD
    Tax Provision725,800,000USD367,300,000USD385,300,000USD520,400,000USD1,250,500,000USD297,200,000USD313,300,000USD109,100,000USD
    Net Income4,504,900,000USD4,412,600,000USD3,953,600,000USD4,338,400,000USD8,075,300,000USD3,513,200,000USD2,115,800,000USD2,444,400,000USD
    Net Income From Continuing Ops4,504,900,000USD4,412,600,000USD3,991,100,000USD4,338,400,000USD8,075,300,000USD3,513,200,000USD2,115,800,000USD2,444,400,000USD
    Ebit5,274,500,000USD4,835,100,000USD4,047,100,000USD4,918,200,000USD9,383,100,000USD3,867,300,000USD2,209,800,000USD2,534,400,000USD
    Ebitda5,818,200,000USD5,318,000,000USD4,047,100,000USD5,259,600,000USD9,669,300,000USD4,103,200,000USD2,420,100,000USD2,682,600,000USD
    Depreciation And Amortization543,700,000USD482,900,000USD421,000,000USD341,400,000USD286,200,000USD235,900,000USD210,300,000USD148,200,000USD
    Reconciled Depreciation543,700,000USD482,900,000USD408,100,000USD341,400,000USD286,200,000USD235,900,000USD210,300,000USD148,200,000USD
    Total Other Income Expense Net1,652,800,000USD789,200,000USD152,200,000USD-526,800,000USD379,000,000USD233,800,000USD219,300,000USD19,100,000USD
    Non Operating Income Net Other———179,300,000USD436,300,000USD290,700,000USD249,500,000USD47,300,000USD
    Net Income Applicable To Common Shares———4,338,400,000USD8,075,300,000USD3,513,200,000USD2,115,800,000USD2,444,400,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets41,730,600,000USD40,868,800,000USD40,558,700,000USD40,169,400,000USD38,219,200,000USD37,545,200,000USD37,759,400,000USD37,441,900,000USD
    Cash And Equivalents2,455,800,000USD———————
    Cash And Short Term Investments7,994,600,000USD8,753,700,000USD8,605,200,000USD8,443,600,000USD7,469,600,000USD8,349,400,000USD9,012,500,000USD9,796,500,000USD
    Short Term Investments5,538,800,000USD5,791,100,000USD5,487,100,000USD5,937,200,000USD5,473,800,000USD5,259,200,000USD6,524,300,000USD7,784,700,000USD
    Long Term Investments9,828,300,000USD9,786,000,000USD10,260,600,000USD10,285,700,000USD10,058,200,000USD9,276,300,000USD8,900,100,000USD8,490,900,000USD
    Total Current Assets18,446,000,000USD18,209,200,000USD18,021,900,000USD17,980,700,000USD16,859,500,000USD17,571,700,000USD18,660,900,000USD19,333,600,000USD
    Other Current Assets801,700,000USD620,900,000USD474,800,000USD595,600,000USD574,300,000USD468,900,000USD349,200,000USD412,000,000USD
    Other Non Current Assets6,687,600,000USD———————
    Total Liabilities10,019,200,000USD———————
    Total Current Liabilities5,530,600,000USD5,107,700,000USD4,368,400,000USD4,425,100,000USD3,667,000,000USD3,566,600,000USD3,944,300,000USD3,661,000,000USD
    Other Current Liabilities3,686,500,000USD———————
    Other Non Current Liabilities2,281,600,000USD———————
    Total Stockholder Equity31,711,400,000USD31,423,600,000USD31,256,900,000USD30,957,800,000USD29,938,900,000USD29,387,600,000USD29,353,600,000USD29,325,900,000USD
    Total Equity Including Noncontrolling Interest31,711,400,000USD———————
    Short Long Term Debt2,706,600,000USD———————
    Long Term Debt1,986,600,000USD1,986,200,000USD1,985,900,000USD1,985,500,000USD1,985,100,000USD1,984,800,000USD1,984,400,000USD1,984,000,000USD
    Deferred Revenue684,800,000USD———————
    Deferred Revenue Non Current220,400,000USD———————
    Net Receivables6,565,400,000USD5,731,000,000USD5,741,100,000USD5,687,100,000USD5,610,000,000USD5,561,000,000USD6,211,900,000USD6,107,100,000USD
    Inventory3,084,300,000USD3,103,600,000USD3,200,800,000USD3,254,400,000USD3,205,600,000USD3,192,400,000USD3,087,300,000USD3,018,000,000USD
    Property Plant Equipment Net5,458,900,000USD5,266,100,000USD5,120,400,000USD5,002,300,000USD4,840,700,000USD4,694,200,000USD4,599,700,000USD4,439,200,000USD
    Intangible Assets1,309,800,000USD1,286,900,000USD1,257,400,000USD1,380,900,000USD1,351,700,000USD1,167,000,000USD1,148,600,000USD1,120,100,000USD
    Accounts Payable1,159,300,000USD1,027,100,000USD939,000,000USD903,800,000USD723,900,000USD705,500,000USD789,500,000USD497,300,000USD
    Common Stock100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Retained Earnings37,621,400,000USD36,423,800,000USD35,797,100,000USD35,045,800,000USD33,680,200,000USD32,384,400,000USD31,672,900,000USD30,755,200,000USD
    Accumulated Other Comprehensive Income-35,800,000USD11,900,000USD77,500,000USD69,000,000USD52,500,000USD29,100,000USD-7,900,000USD60,200,000USD
    Total Liab—9,445,200,000USD9,301,800,000USD9,211,600,000USD8,280,300,000USD8,157,600,000USD8,405,800,000USD8,116,000,000USD
    Other Current Liab—2,724,400,000USD2,876,400,000USD2,975,700,000USD2,461,200,000USD2,241,800,000USD2,313,900,000USD2,536,500,000USD
    Capital Stock—100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Cash—2,962,600,000USD3,118,100,000USD2,506,400,000USD1,995,800,000USD3,090,200,000USD2,488,200,000USD2,011,800,000USD
    Current Deferred Revenue—636,200,000USD553,000,000USD545,600,000USD481,900,000USD619,300,000USD627,700,000USD627,200,000USD
    Net Debt—-256,400,000USD-412,200,000USD199,100,000USD709,300,000USD-385,400,000USD216,200,000USD692,200,000USD
    Short Term Debt—720,000,000USD37,800,000USD—————
    Short Long Term Debt Total—2,706,200,000USD2,705,900,000USD2,705,500,000USD2,705,100,000USD2,704,800,000USD2,704,400,000USD2,704,000,000USD
    Common Stock Shares Outstanding—107,700,000shares107,500,000shares107,200,000shares108,600,000shares111,200,000shares113,800,000shares116,200,000shares
    Non Current Assets Total—22,659,600,000USD22,536,800,000USD22,188,700,000USD21,359,700,000USD19,973,500,000USD19,098,500,000USD18,108,300,000USD
    Non Current Liabilities Total—4,337,500,000USD4,933,400,000USD4,786,500,000USD4,613,300,000USD4,591,000,000USD4,461,500,000USD4,455,000,000USD
    Non Current Liabilities Other—2,126,200,000USD2,018,800,000USD1,861,800,000USD1,701,900,000USD1,674,400,000USD1,571,400,000USD1,543,600,000USD
    Non Currrent Assets Other—2,129,700,000USD1,821,200,000USD1,673,100,000USD1,536,900,000USD1,393,100,000USD1,136,000,000USD1,043,000,000USD
    Net Working Capital—13,101,500,000USD13,653,500,000USD13,555,600,000USD13,192,500,000USD14,005,100,000USD14,716,600,000USD15,672,600,000USD
    Unclassified Non Current Assets—4,190,900,000USD1,781,200,000USD3,846,700,000USD3,572,200,000USD3,442,900,000USD1,828,900,000USD3,015,100,000USD
    Unclassified Non Current Liabilities—225,100,000USD928,700,000USD939,200,000USD926,300,000USD931,800,000USD905,700,000USD927,400,000USD
    Unclassified Equity—-5,012,300,000USD-4,617,900,000USD-4,157,200,000USD-3,794,000,000USD-3,026,100,000USD-2,311,600,000USD-1,489,700,000USD
    Other Assets——2,296,000,000USD———1,485,200,000USD—
    Property Plant Equipment Gross——7,734,700,000USD———6,886,600,000USD—
    Unclassified Current Liabilities——————213,200,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets40,558,700,000USD37,759,400,000USD33,080,200,000USD29,214,500,000USD25,434,800,000USD17,163,300,000USD14,805,200,000USD11,734,500,000USD
    Intangible Assets1,257,400,000USD1,148,600,000USD1,038,600,000USD915,500,000USD6,700,000USD———
    Other Current Assets474,800,000USD349,200,000USD386,600,000USD411,200,000USD332,400,000USD1,164,000,000USD273,700,000USD243,300,000USD
    Total Liab9,301,800,000USD8,405,800,000USD7,107,100,000USD6,550,500,000USD6,666,000,000USD6,138,000,000USD3,715,500,000USD2,977,200,000USD
    Total Stockholder Equity31,256,900,000USD29,353,600,000USD25,973,100,000USD22,664,000,000USD18,768,800,000USD11,025,300,000USD11,089,700,000USD8,757,300,000USD
    Other Current Liab2,876,400,000USD2,313,900,000USD2,357,900,000USD2,073,900,000USD1,880,500,000USD122,400,000USD1,197,600,000USD772,100,000USD
    Common Stock100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Capital Stock100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Retained Earnings35,797,100,000USD31,672,900,000USD27,260,300,000USD23,306,700,000USD18,968,300,000USD10,893,000,000USD7,379,800,000USD5,254,300,000USD
    Other Assets2,296,000,000USD—-1USD747,600,000USD555,200,000USD2,770,000,000USD913,300,000USD910,600,000USD
    Cash3,118,100,000USD2,488,200,000USD2,730,000,000USD3,105,900,000USD2,885,600,000USD2,193,700,000USD1,617,800,000USD1,467,700,000USD
    Cash And Short Term Investments8,605,200,000USD9,012,500,000USD10,844,800,000USD7,742,300,000USD5,694,700,000USD6,722,600,000USD3,214,300,000USD4,564,900,000USD
    Total Current Assets18,021,900,000USD18,660,900,000USD19,479,200,000USD15,884,100,000USD14,014,900,000USD12,753,900,000USD7,689,100,000USD7,959,300,000USD
    Total Current Liabilities4,368,400,000USD3,944,300,000USD3,423,400,000USD3,141,300,000USD3,932,500,000USD2,806,800,000USD2,096,600,000USD1,352,000,000USD
    Current Deferred Revenue553,000,000USD627,700,000USD458,900,000USD477,900,000USD442,000,000USD577,700,000USD591,700,000USD452,500,000USD
    Net Debt-412,200,000USD216,200,000USD-27,100,000USD-404,500,000USD-185,900,000USD502,000,000USD-903,900,000USD-759,200,000USD
    Short Term Debt37,800,000USD——720,000,000USD719,700,000USD1,631,200,000USD—90,800,000USD
    Short Long Term Debt Total2,705,900,000USD2,704,400,000USD2,702,900,000USD2,701,400,000USD2,699,700,000USD3,609,700,000USD713,900,000USD799,300,000USD
    Long Term Debt1,985,900,000USD1,984,400,000USD1,982,900,000USD1,981,400,000USD1,980,000,000USD1,978,500,000USD——
    Long Term Investments10,260,600,000USD8,900,100,000USD5,396,500,000USD6,591,800,000USD6,838,000,000USD3,135,600,000USD3,256,800,000USD1,755,000,000USD
    Short Term Investments5,487,100,000USD6,524,300,000USD8,114,800,000USD4,636,400,000USD2,809,100,000USD1,393,300,000USD1,596,500,000USD1,342,200,000USD
    Net Receivables5,741,100,000USD6,211,900,000USD5,667,300,000USD5,328,700,000USD6,036,500,000USD4,114,700,000USD2,785,600,000USD2,243,200,000USD
    Inventory3,200,800,000USD3,087,300,000USD2,580,500,000USD2,401,900,000USD1,951,300,000USD1,916,600,000USD1,415,500,000USD1,151,200,000USD
    Accounts Payable939,000,000USD789,500,000USD606,600,000USD589,200,000USD564,000,000USD475,500,000USD418,100,000USD218,200,000USD
    Property Plant Equipment Net5,120,400,000USD4,599,700,000USD4,146,400,000USD3,763,000,000USD3,482,200,000USD3,221,600,000USD2,890,400,000USD2,575,800,000USD
    Property Plant Equipment Gross7,734,700,000USD6,886,600,000USD6,125,200,000USD5,432,200,000USD4,880,300,000USD3,221,600,000USD2,890,400,000USD2,575,800,000USD
    Accumulated Other Comprehensive Income77,500,000USD-7,900,000USD-80,900,000USD-238,800,000USD-26,200,000USD29,300,000USD21,100,000USD-12,300,000USD
    Common Stock Shares Outstanding108,600,000shares115,100,000shares113,700,000shares113,500,000shares112,200,000shares115,100,000shares114,600,000shares114,800,000shares
    Non Current Assets Total22,536,800,000USD19,098,500,000USD13,601,000,000USD13,330,400,000USD11,419,900,000USD4,409,400,000USD7,116,100,000USD3,775,200,000USD
    Non Current Liabilities Total4,933,400,000USD4,461,500,000USD3,683,700,000USD3,409,200,000USD2,733,500,000USD3,331,200,000USD1,618,900,000USD1,625,200,000USD
    Non Current Liabilities Other2,018,800,000USD1,571,400,000USD854,100,000USD1,427,800,000USD753,500,000USD1,462,100,000USD1,618,900,000USD825,900,000USD
    Non Currrent Assets Other1,821,200,000USD1,136,000,000USD444,100,000USD336,400,000USD216,100,000USD328,900,000USD144,700,000USD370,700,000USD
    Net Working Capital13,653,500,000USD14,716,600,000USD16,055,800,000USD17,495,600,000USD17,069,500,000USD7,081,700,000USD5,592,500,000USD5,004,800,000USD
    Unclassified Non Current Assets1,781,200,000USD3,314,100,000USD2,575,400,000USD976,100,000USD321,700,000USD-5,046,700,000USD-89,100,000USD-1,836,900,000USD
    Unclassified Non Current Liabilities928,700,000USD905,700,000USD846,700,000USD-707,800,000USD-515,300,000USD-744,900,000USD-889,000,000USD-26,600,000USD
    Unclassified Equity-4,617,900,000USD-2,311,600,000USD-1,206,500,000USD-404,100,000USD8,087,400,000USD6,716,100,000USD4,428,500,000USD3,911,500,000USD
    Unclassified Current Liabilities—213,200,000USD—-719,700,000USD326,300,000USD—-110,800,000USD-181,600,000USD
    Good Will——-1USD—-6,844,700,000USD———
    Other Liab———707,800,000USD515,300,000USD635,500,000USD889,000,000USD825,900,000USD
    Net Tangible Assets———21,748,500,000USD18,768,800,000USD11,025,300,000USD11,089,700,000USD8,757,300,000USD
    Treasury Stock————-8,260,900,000USD-6,613,300,000USD-739,900,000USD-396,400,000USD
    Unclassified Current Assets—————1,971,600,000USD—1,511,700,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Net Income2,024,100,000USD
    Depreciation246,900,000USD
    Stock Based Compensation500,400,000USD
    Deferred Income Tax-290,400,000USD
    Other Non Cash Items23,600,000USD
    Change To Account Receivables-837,300,000USD
    Change To Inventory-1,600,000USD
    Change To Liabilities743,900,000USD
    Change In Working Capital-612,700,000USD
    Operating Cash Flow1,891,900,000USD
    Capital Expenditures-470,800,000USD
    Net Investments49,100,000USD
    Other Investing Activities-99,900,000USD
    Unclassified Investing Cash Flow0USD
    Investing Cash Flow-521,600,000USD
    Common Stock Issuance212,300,000USD
    Net Common Stock Issuance-1,832,200,000USD
    Common Dividends Paid-194,600,000USD
    Other Financing Activities0USD
    Unclassified Financing Cash Flow0USD
    Financing Cash Flow-2,026,800,000USD
    Effect Of Forex Changes On Cash-1,200,000USD
    Change In Cash-657,700,000USD
    End Cash Flow2,466,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income727,200,000USD844,600,000USD1,460,000,000USD1,391,600,000USD808,700,000USD917,700,000USD1,340,600,000USD1,432,300,000USD
    Depreciation123,200,000USD145,000,000USD136,700,000USD135,100,000USD126,900,000USD126,400,000USD121,700,000USD120,700,000USD
    Stock Based Compensation257,400,000USD249,300,000USD237,000,000USD251,700,000USD255,700,000USD304,400,000USD225,100,000USD223,200,000USD
    Other Non Cash Items144,500,000USD158,400,000USD-561,400,000USD-270,900,000USD-136,700,000USD280,900,000USD-695,600,000USD-395,600,000USD
    Change To Account Receivables1,200,000USD-51,200,000USD-80,300,000USD-28,200,000USD657,800,000USD-117,800,000USD-388,900,000USD-494,100,000USD
    Change To Inventory26,600,000USD2,100,000USD-82,600,000USD-42,500,000USD-152,300,000USD-117,700,000USD-164,400,000USD-181,800,000USD
    Change In Working Capital-77,400,000USD5,900,000USD625,000,000USD-227,900,000USD129,600,000USD-86,400,000USD468,000,000USD-908,500,000USD
    Total Cash From Operating Activities1,078,900,000USD1,170,700,000USD1,618,700,000USD1,144,400,000USD1,045,100,000USD1,262,800,000USD1,291,200,000USD354,000,000USD
    Capital Expenditures-230,600,000USD-248,700,000USD-201,400,000USD-176,800,000USD-271,500,000USD-267,000,000USD-183,600,000USD-210,900,000USD
    Free Cash Flow848,300,000USD922,000,000USD1,417,300,000USD967,600,000USD773,600,000USD995,800,000USD1,107,600,000USD143,100,000USD
    Investments-149,400,000USD511,300,000USD-402,900,000USD-1,094,000,000USD647,500,000USD350,600,000USD-574,400,000USD-557,200,000USD
    Total Cashflows From Investing Activities-428,900,000USD220,300,000USD-402,900,000USD-1,094,000,000USD647,500,000USD350,600,000USD-574,400,000USD-557,200,000USD
    Total Cash From Financing Activities-802,200,000USD-780,100,000USD-717,900,000USD-1,128,200,000USD-1,089,200,000USD-1,135,500,000USD-634,000,000USD-478,100,000USD
    Dividends Paid-97,800,000USD-92,700,000USD-91,200,000USD-92,600,000USD-93,800,000USD——0USD
    Sale Purchase Of Stock-794,300,000USD-671,700,000USD-664,000,000USD-1,061,500,000USD-1,045,700,000USD-973,000,000USD-735,100,000USD-603,900,000USD
    Issuance Of Capital Stock163,100,000USD503,500,000USD40,300,000USD31,500,000USD60,600,000USD90,900,000USD254,700,000USD437,600,000USD
    Change In Cash-153,100,000USD610,600,000USD497,500,000USD-1,077,400,000USD604,000,000USD477,200,000USD83,600,000USD-681,600,000USD
    Begin Period Cash Flow3,123,700,000USD2,513,100,000USD2,015,600,000USD3,093,000,000USD2,489,000,000USD2,011,800,000USD1,928,200,000USD2,602,000,000USD
    End Period Cash Flow2,970,600,000USD3,123,700,000USD2,513,100,000USD2,015,600,000USD3,093,000,000USD2,489,000,000USD2,011,800,000USD1,928,200,000USD
    Other Cashflows From Investing Activities-48,900,000USD—-43,300,000USD-187,800,000USD-42,200,000USD—-38,200,000USD-371,700,000USD
    Other Cashflows From Financing Activities-73,200,000USD-519,200,000USD-3,000,000USD-5,600,000USD-10,300,000USD-253,400,000USD-153,600,000USD-311,800,000USD
    Unclassified Operating Cash Flow-96,000,000USD-232,500,000USD-278,600,000USD-135,200,000USD-139,100,000USD-280,200,000USD-168,600,000USD-118,100,000USD
    Unclassified Financing Cash Flow163,100,000USD503,500,000USD40,300,000USD31,500,000USD60,600,000USD90,900,000USD254,700,000USD437,600,000USD
    Unclassified Investing Cash Flow—-42,300,000USD244,700,000USD364,600,000USD313,700,000USD267,000,000USD221,800,000USD582,600,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income4,504,900,000USD4,412,600,000USD3,953,600,000USD4,338,400,000USD8,075,300,000USD3,513,200,000USD2,115,800,000USD2,444,400,000USD
    Depreciation543,700,000USD482,900,000USD421,000,000USD341,400,000USD286,200,000USD235,900,000USD210,300,000USD148,200,000USD
    Stock Based Compensation993,700,000USD982,800,000USD885,000,000USD725,000,000USD601,700,000USD432,000,000USD464,300,000USD427,400,000USD
    Other Non Cash Items-810,600,000USD-82,200,000USD266,300,000USD599,800,000USD181,700,000USD-135,000,000USD-29,300,000USD12,100,000USD
    Change To Account Receivables498,100,000USD-554,000,000USD-338,800,000USD707,800,000USD-1,927,400,000USD-1,356,100,000USD-473,100,000USD-268,900,000USD
    Change To Inventory-275,300,000USD-619,700,000USD-271,700,000USD-696,500,000USD-494,300,000USD-529,400,000USD-335,500,000USD-387,900,000USD
    Change In Working Capital532,600,000USD-618,300,000USD-94,100,000USD-243,300,000USD-1,916,500,000USD-1,503,600,000USD-200,500,000USD-697,000,000USD
    Total Cash From Operating Activities4,978,900,000USD4,420,500,000USD4,594,000,000USD5,014,900,000USD7,081,300,000USD2,618,100,000USD2,430,000,000USD2,195,100,000USD
    Capital Expenditures-898,400,000USD-755,900,000USD-926,400,000USD-590,100,000USD-551,900,000USD-614,600,000USD-429,600,000USD-383,100,000USD
    Free Cash Flow4,080,500,000USD3,664,600,000USD3,667,600,000USD4,424,800,000USD6,529,400,000USD2,003,500,000USD2,000,400,000USD1,812,000,000USD
    Investments587,900,000USD-2,468,100,000USD-4,976,600,000USD-1,937,400,000USD-4,832,800,000USD544,000,000USD-1,598,200,000USD-1,069,900,000USD
    Total Cashflows From Investing Activities-629,100,000USD-2,468,100,000USD-3,185,100,000USD-3,784,600,000USD-5,384,700,000USD-70,600,000USD-2,027,800,000USD-1,463,000,000USD
    Total Cash From Financing Activities-3,715,400,000USD-2,200,500,000USD-1,790,100,000USD-1,009,000,000USD-1,005,800,000USD-1,970,500,000USD-252,100,000USD-77,100,000USD
    Dividends Paid-370,300,000USD0USD0USD—————
    Sale Purchase Of Stock-3,970,700,000USD-3,632,400,000USD-2,235,000,000USD-2,528,500,000USD-2,678,100,000USD-6,527,600,000USD-463,900,000USD-191,600,000USD
    Issuance Of Capital Stock635,900,000USD1,465,300,000USD1,217,100,000USD1,519,500,000USD1,672,300,000USD2,575,200,000USD211,800,000USD114,500,000USD
    Change In Cash634,700,000USD-248,800,000USD-381,600,000USD221,300,000USD690,800,000USD577,000,000USD150,100,000USD655,000,000USD
    Begin Period Cash Flow2,489,000,000USD2,737,800,000USD3,119,400,000USD2,898,100,000USD2,207,300,000USD1,630,300,000USD1,480,200,000USD825,200,000USD
    End Period Cash Flow3,123,700,000USD2,489,000,000USD2,737,800,000USD3,119,400,000USD2,898,100,000USD2,207,300,000USD1,630,300,000USD1,480,200,000USD
    Other Cashflows From Investing Activities-315,300,000USD-105,600,000USD-926,400,000USD-1,026,800,000USD-551,900,000USD-614,600,000USD-429,600,000USD-1,079,900,000USD
    Other Cashflows From Financing Activities-10,300,000USD-33,400,000USD-700,600,000USD-3,784,600,000USD1USD-70,600,000USD-188,000,000USD-187,200,000USD
    Unclassified Operating Cash Flow-785,400,000USD-757,300,000USD-837,800,000USD-746,400,000USD-147,100,000USD75,600,000USD-130,600,000USD-140,000,000USD
    Unclassified Financing Cash Flow635,900,000USD1,465,300,000USD1,145,500,000USD5,304,100,000USD1,672,299,999USD2,645,800,000USD-1,582,100,000USD-1,680,200,000USD
    Unclassified Investing Cash Flow—861,500,000USD3,644,300,000USD-230,300,000USD551,900,000USD614,600,000USD429,600,000USD1,069,900,000USD
    Change To Liabilities———-106,000,000USD745,900,000USD267,000,000USD738,500,000USD15,500,000USD
    Net Borrowings———0USD0USD1,981,900,000USD1,981,900,000USD1,981,900,000USD
    Cash And Cash Equivalents Changes———221,300,000USD690,800,000USD577,000,000USD150,100,000USD655,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Bayer Collaboration Profit Share Rate

    Period endPeriodValueUnitSource
    2026-06-30quarterly34percentDisclosure

    Sanofi Collaboration Profit Share Rate

    Period endPeriodValueUnitSource
    2026-06-30quarterly33percentDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2022Quarterly · 2022-03-31ProductAmounts Recognized In Connection With Up Front Payments18,100,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductCollaboration Revenue1,232,500,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductProduct And Service Other752,600,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductRegenerons Share Of Commercial Expenses-9,200,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductRegenerons Share Of Research And Development Expenses-9,700,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductReimbursement For Manufacturing Of Commercial Supplies160,800,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductReimbursement For Manufacturing Of Ex Commercial Supplies2,000,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductReimbursement Of Commercialization Related Expenses110,700,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductReimbursement Of Research And Development Expenses58,000,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductRonapreve216,300,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductSales Based Milestone Earned50,000,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductSanofis Shareof Libtayo U.S.Gross Profits-32,300,000USD0001804220-22-000015
    Q1 2022Quarterly · 2022-03-31ProductShare Of Profit Losses In Connection With Commercialization415,300,000USD0001804220-22-000015
    Q4 2020Quarterly · 2020-12-31ProductProduct1,621,800,000USDLegacy provider
    Q4 2020Quarterly · 2020-12-31ProductProduct And Service Other801,100,000USDLegacy provider
    FY 2020Yearly · 2020-12-31ProductProduct5,567,600,000USD0001804220-21-000008
    FY 2020Yearly · 2020-12-31ProductProduct And Service Other2,929,500,000USD0001804220-21-000008
    Q3 2020Quarterly · 2020-09-30ProductProduct1,482,200,000USD0001804220-20-000030
    Q3 2020Quarterly · 2020-09-30ProductProduct And Service Other811,800,000USD0001804220-20-000030
    Q2 2020Quarterly · 2020-06-30ProductProduct1,226,900,000USD0001804220-20-000022
    Q2 2020Quarterly · 2020-06-30ProductProduct And Service Other725,100,000USD0001804220-20-000022
    Q1 2020Quarterly · 2020-03-31ProductProduct1,236,700,000USD0001804220-20-000011
    Q1 2020Quarterly · 2020-03-31ProductProduct And Service Other591,500,000USD0001804220-20-000011
    Q3 2019Quarterly · 2019-09-30ProductProduct1,238,300,000USD0001804220-20-000030
    Q3 2019Quarterly · 2019-09-30ProductProduct And Service Other630,500,000USD0001804220-20-000030
    Q3 2019Quarterly · 2019-09-30ProductReimbursement For Manufacturing Of Commercial Supplies85,400,000USD0001804220-20-000030
    Q3 2019Quarterly · 2019-09-30ProductSales Based Milestone0USD0001804220-20-000030
    Q3 2019Quarterly · 2019-09-30ProductShare Of Profit Losses In Connection With Commercialization94,200,000USD0001804220-20-000030
    Q2 2019Quarterly · 2019-06-30ProductProduct1,205,300,000USD0001804220-20-000022
    Q2 2019Quarterly · 2019-06-30ProductProduct And Service Other645,700,000USD0001804220-20-000022
    Q2 2019Quarterly · 2019-06-30ProductReimbursement For Manufacturing Of Commercial Supplies43,900,000USD0001804220-20-000022
    Q2 2019Quarterly · 2019-06-30ProductShare Of Profit Losses In Connection With Commercialization38,800,000USD0001804220-20-000022
    Q1 2019Quarterly · 2019-03-31ProductProduct1,104,400,000USD0001804220-20-000011
    Q1 2019Quarterly · 2019-03-31ProductProduct And Service Other281,500,000USD0001804220-20-000011
    Q1 2019Quarterly · 2019-03-31ProductReimbursement For Manufacturing Of Commercial Supplies14,500,000USD0001804220-20-000011
    Q1 2019Quarterly · 2019-03-31ProductShare Of Profit Losses In Connection With Commercialization-27,800,000USD0001804220-20-000011
    FY 2018Yearly · 2018-12-31ProductAmounts Recognized In Connection With Up Front Payments243,800,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductProduct4,106,200,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductProduct And Service Other1,553,900,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductRegenerons Share Of Other Expenses-16,100,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductRegenerons Share Of Research And Development Expenses-47,700,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductReimbursement For Manufacturing Of Commercial Supplies113,700,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductReimbursement Of Commercialization Related Expenses426,100,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductReimbursement Of Research And Development Expenses577,100,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductSales Based Milestone0USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductSanofis Share Of Libtayo USGross Profits-6,800,000USD0001804220-21-000008
    FY 2018Yearly · 2018-12-31ProductShare Of Profits Losses In Connection With Commercialization-239,400,000USD0001804220-21-000008

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.